Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane

Pflugers Arch. 2021 Jun;473(6):883-896. doi: 10.1007/s00424-021-02560-z. Epub 2021 May 24.

Abstract

An acquired dysregulation of airway secretion is likely involved in the pathophysiology of chronic bronchitis and chronic obstructive pulmonary disease (COPD). Nowadays, it is widely known that several kinds of long-acting bronchodilators reduce the frequency of COPD exacerbations. However, limited data are available concerning the complementary additive effects on airflow obstruction. Using an optical method and a selective pH indicator, we succeeded in evaluating the gland secretion rate and the pH in swine tracheal membrane. A physiologically relevant concentration of acetylcholine (ACh) 100 nM induced a gradual increase in the amount of gland secretion. Lipopolysaccharides (LPS) accelerated the ACh-induced secretory responses up to around threefold and lowered the pH level significantly. Long-acting β2-agonists (LABAs) including indacaterol (IND), formoterol, and salmeterol restored the LPS-induced changes in both the hypersecretion and acidification. The subsequent addition of the long-acting muscarine antagonist, glycopyrronium, further increased the pH values. Two different inhibitors for cystic fibrosis transmembrane conductance regulator (CFTR), NPPB and CFTRinh172, abolished the IND-mediated pH normalization in the presence of both ACh and ACh + LPS. Both immunofluorescence staining and western blotting analysis revealed that LPS downregulated the abundant expression of CFTR protein. However, IND did not restore the LPS-induced decrease in CFTR expression on Calu-3 cells. These findings suggest that the activation of cAMP-dependent HCO3- secretion through CFTR would be partly involved in the IND-mediated pH normalization in gland secretion and may be suitable for the maintenance of airway defense against exacerbating factors including LPS.

Keywords: Bicarbonate; CFTR; Calu-3; LABA; Submucosal gland.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / metabolism
  • Adrenergic beta-2 Receptor Agonists / pharmacology*
  • Adrenergic beta-2 Receptor Agonists / therapeutic use
  • Animals
  • Bicarbonates / metabolism
  • Bronchodilator Agents / pharmacology*
  • Bronchodilator Agents / therapeutic use
  • Cell Line, Tumor
  • Cells, Cultured
  • Cystic Fibrosis Transmembrane Conductance Regulator / metabolism
  • Glycopyrrolate / pharmacology
  • Glycopyrrolate / therapeutic use
  • Humans
  • Hydrogen-Ion Concentration
  • Indans / pharmacology*
  • Indans / therapeutic use
  • Lipopolysaccharides / toxicity
  • Mucins / metabolism*
  • Muscarinic Antagonists / pharmacology
  • Muscarinic Antagonists / therapeutic use
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / etiology
  • Pulmonary Disease, Chronic Obstructive / metabolism*
  • Quinolones / pharmacology*
  • Quinolones / therapeutic use
  • Respiratory Mucosa / drug effects
  • Respiratory Mucosa / metabolism
  • Swine
  • Trachea / drug effects
  • Trachea / metabolism*

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Bicarbonates
  • Bronchodilator Agents
  • Indans
  • Lipopolysaccharides
  • Mucins
  • Muscarinic Antagonists
  • Quinolones
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • indacaterol
  • Acetylcholine
  • Glycopyrrolate